Find participating medical centers and current study status in each of them

    Find participating medical centers

    A Dose Escalation and Expansion Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

    • Cancer
    • Melanoma
    • Metastatic Melanoma
    • Lung Cancer
    • Non-Small Cell Lung Cancer (NSCLC)
    • Small Cell Lung Cancer
    • Solid Tumors
    • Esophageal Squamous Cell Carcinoma